Clinical beta

FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.

Drug Monograph

Cefotaxime

Cefotaxime

Third-generation cephalosporin (IV)

MeningitisSepsisq6-8hΞ²-lactam

Indication

Sepsis β€’ meningitis β€’ CAP (IV) β€’ intra-abdominal (combo) β€’ neonatal sepsis (per NICU protocol)

At a glance

INDICATIONS (CORE USE)

Serious gram-negative infections; meningitis component; no ceftriaxone–calcium neonatal issue β€” shorter half-life β†’ more frequent dosing.

ADULT DOSE (STANDARD)

1–2 g IV q6–8h (severe); moderate infections lower end

MAX DOSE

~12 g/day adult in extreme cases (institution capped)

Route

IV, IM

PEDIATRIC DOSE

Neonatal/pediatric meningitis dosing per mg/kg q6h protocols

Do not miss

Must-not-miss safety points

Major warning

- Ξ²-lactam anaphylaxis - Renal adjustment required in CKD - ESBL / AmpC inducible organisms β€” treatment failure risk in wrong syndrome - Not anti-MRSA / not anti-enterococcus

Indications

USE IF: Alternative to ceftriaxone when q24h agent not ideal; neonatal sepsis/meningitis per NICU; serious GNR infection. AVOID IF: Pseudomonas (use anti-pseudomonal beta-lactam), MRSA, ESBL risk without carbapenem strategy.

Primary

  • Severe sepsis / bacteremia due to susceptible Enterobacterales
  • Meningitis (combination therapy per age)
  • Hospital-acquired pneumonia only if susceptibility and adequate spectrum (often combined)

Secondary

  • Surgical prophylaxis in some centers (cefazolin often preferred)
  • Pelvic infection combinations

Other

  • Neonatal sepsis when protocol specifies cefotaxime

Dosing

STANDARD (ADULT PO)

1 g IV q8h moderate; 2 g IV q6–8h severe

ADULT DOSE

1 g IV q8h moderate; 2 g IV q6–8h severe; some protocols use continuous infusion extensions

PEDIATRIC DOSE

Highly weight- and indication-specific β€” NICU/peds reference mandatory.

MAX DOSE

Up to ~12 g/day in selected adult ICU protocols β€” pharmacy oversight.

Practical Note

Shorter half-life than ceftriaxone β€” cannot assume q24h interchangeability.

Warnings

Clinical warnings

  • **Ξ²-lactam allergy β€” immediate** (anaphylaxis, angioedema, bronchospasm, hypotension) β†’ **avoid** this agent; use non–β-lactam alternative
  • **Ξ²-lactam allergy β€” non-severe** (maculopapular rash without systemic anaphylaxis features) β†’ **caution**; risk/benefit + allergy/ID pathway; graded challenge or test dose **only** per protocol β€” do not dismiss automatically
  • **Neurotoxicity:** encephalopathy, confusion, myoclonus, seizures β€” **higher risk with CKD, elderly, dose accumulation** (notably cefepime, carbapenems, high-dose penicillins)
  • New CNS symptoms + renal impairment on IV Ξ²-lactam β†’ **hold dose**, check levels/exposure, rule out other causes
  • C. diff
  • Neurotoxicity at extreme doses + renal failure (class effect)

Adverse effects

  • rash
  • phlebitis
  • diarrhea
  • transient LFT elevation

Contraindications

  • Severe cephalosporin anaphylaxis when cephalosporin avoided

Drug interactions

  • Probenecid
  • Aminoglycoside synergy β€” monitor renal function

Special populations

Pediatrics

Neonatal/pediatric meningitis dosing per mg/kg q6h protocols

Pregnancy

Pregnancy: acceptable when indicated.

Lactation

compatible generally.

Renal impairment

Reduce frequency/dose in CKD; HD supplemental doses per pharmacy. **CrCl scaffold (FMBM β€” titrate to FDA/SFDA label + institutional pharmacy nomogram):** - **CrCl β‰₯50** β†’ standard interval (per Adult dosing card) - **CrCl 10–50** β†’ extend interval and/or reduce dose (often q12–24h or ↓ dose β€” **product-specific**) - **CrCl <10** β†’ maximal interval extension / dose reduction; **HD: redose post-dialysis** per protocol; AKI β†’ re-estimate CrCl; **neuro signs** β†’ hold/adjust

Hepatic impairment

Severe hepatic failure β€” monitor; combined with renal failure adjust aggressively.

Elderly

Renal dosing; polypharmacy interactions.

Administration

IV intermittent infusion; compatible with standard fluids per stability.

Monitoring

  • Monitor: - ICU or CKD β†’ **creatinine daily** β†’ underdosing in AKI vs accumulation / **neurotoxicity** if not adjusted - New confusion / myoclonus / seizures + renal impairment on IV Ξ²-lactam β†’ **hold dose** β†’ evaluate encephalopathy - Serious GNR infection β†’ extended-infusion / pharmacy optimization per protocol - Renal function - Clinical sepsis response - Levels not routine
  • Recheck: - No clinical improvement at 48–72h β†’ reassess diagnosis, resistance, source control, and drug interactions - If targets not met after reassessment of dose, organ function, and interactions β†’ escalate per protocol (DO NOT continue blindly)

Overdose / toxicity

Clinical Picture

**Life-threatening (first):** **CNS toxicity** β€” seizures, encephalopathy, agitation, myoclonus, coma (**↑ CKD, elderly, accumulation**; cefepime, carbapenems, high-dose penicillins). **Allergic:** anaphylaxis / angioedema (separate pathway). **Secondary:** nausea/vomiting/diarrhea mainly with acute massive **oral** co-ingestion or local infusion reaction.

Immediate Actions

Stop Ξ²-lactam β†’ ABCs β†’ **seizure precautions**; benzos if seizures; check renal function / dose vs CrCl; anaphylaxis β†’ epinephrine + ACLS

Antidote

No specific antidote; treat complications (e.g. anaphylaxis β†’ epinephrine per ACLS)

Decontamination

Stop infusion; recent large PO load β†’ charcoal if protected airway + early presentation

Escalation

Status epilepticus, coma, refractory seizures β†’ **ICU**; **severe CNS toxicity or AKI with accumulation β†’ consider hemodialysis** for dialyzable agents β€” nephrology + pharmacy; persistent anaphylaxis β†’ ICU

Clinical pearls

Common mistakes, resistance logic, and bedside traps

High-Yield Summary

Third-gen workhorse with **q6–8h** schedule β€” neonatal-friendly vs ceftriaxone in many protocols. Renal adjust.

Clinical pearls

Choose cefotaxime vs ceftriaxone by kinetics, neonatal safety, and hepato-renal comorbidity. Stewardship: combo regimens for intra-abd per guideline. *Stewardship (all antimicrobials):* Empiric choice β†’ syndrome severity + **local antibiogram**; shortest effective course.

Stewardship & safety

  • Renal dose
  • Meningitis dosing
  • C. diff

Pharmacokinetics

Renal elimination predominant; TΒ½ shorter than ceftriaxone; CSF penetration adequate for meningitis dosing.

Mechanism of action

Third-gen cephalosporin β€” PBP binding, bactericidal.

Common brand names

Saudi Arabia

Claforan, Cefotaxime

Global

(placeholder β€” verify local formulary)

Common trade names are curated examples only β€” formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.

Country practice notes

  • Empiric choice β†’ tie to syndrome, severity, and local antibiogram β€” not habit.
  • IV β†’ PO step-down when oral bioavailability and susceptibility allow.
  • Do not use antibiotics for uncomplicated viral illness β€” stewardship.

References

Saudi Arabia

  • SFDA (Saudi Food & Drug Authority)
  • Saudi National Formulary / MOH (where available)

International

  • WHO Model List of Essential Medicines (verify current edition)
  • US FDA or EU EMA product information (when national SmPC is unavailable)
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling
  • Sanford Guide
  • IDSA / ESCMID (indication-specific)
  • Local antimicrobial stewardship / hospital formulary
  • FDA / SFDA / regional product labeling

Do not miss

  • Uncomplicated viral URI/bronchitis β†’ antibiotics rarely indicated
  • Narrow or stop when susceptibilities + clinical stability allow
  • Do not under-dose meningitis.
  • AmpC/ESBL pitfalls in Enterobacter/Citrobacter scenarios.
  • Renal dose
  • Meningitis dosing
  • C. diff